Company Overview
Snapshot
Founded in January 2019 by Noam Solomon, Luis Voloch, and Ansuman Satpathy, Immunai operates with 51–200 employees. The company has raised $295 million across three funding rounds from 14 investors. In October 2021, Immunai announced a $215 million Series B round, highlighting the maturation of its immune cell atlas.
Business overview
Immunai develops a proprietary dataset of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface enable researchers to comprehensively view and interrogate data, deriving novel conclusions on underlying disease mechanisms. Its platform is currently used to develop and refine cell therapies for neuroblastoma in collaboration with the Baylor College of Medicine. Immunai operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, medical decision support, and drug discovery and development, leveraging artificial intelligence, machine learning, and deep learning technologies.
Strategic signal
In June 2026, Immunai announced a collaboration with Boehringer Ingelheim to decode T-cell dysfunction, a common factor in cancer and autoimmune disorders. This partnership signals Immunai's continued strategic validation in leveraging its AI-based immune system modeling platform for critical drug development challenges, demonstrating its value to major pharmaceutical companies and its potential to advance therapeutic understanding in complex diseases.
Log in to access full profile ›Company Intelligence Q&A
- What was Immunai's most recent strategic partnership?
- In June 2026, Immunai partnered with Boehringer Ingelheim to focus on decoding T-cell dysfunction, a shared mechanism in cancer and autoimmune disorders.
- When did Immunai last raise a funding round and what was the amount?
- In October 2021, Immunai raised $215 million in a Series B funding round. Koch Disruptive Technologies was a lead investor in this round.
- What was the nature of Immunai's collaboration with Teva?
- In November 2024, Immunai and Teva launched a multi-year AI collaboration aimed at enhancing precision in immunology and oncology trials by utilizing Immunai’s immune system mapping tools.
- Which company did Immunai acquire in 2021?
- In August 2021, Immunai acquired Nebion, making it a subsidiary of the New York-based company.
- What was the purpose of Immunai's partnership announced in January 2026?
- In January 2026, Immunai announced a collaboration aimed at improving the understanding of patient biology within clinical trials.